Prolonged stay predictors in patients admitted with chronic obstructive pulmonary disease acute exacerbation

María-Teresa García-Sanz, Francisco-Javier González-Barcala¹,²,³,⁴, Juan-Carlos Cánive-Gómez⁵, Nuria García-Couceiro⁶, Sara Alonso-Acuña⁶, José-Martín Carreira⁷

Department of Emergency, Salnés County Hospital, Vilagarcía de Arousa, ¹Department of Medicine, University of Santiago de Compostela, ²Spanish Biomedical Research Networking Centre-CIBERES, Barcelona, ³Department of Respiratory Medicine, University Hospital Complex of Santiago de Compostela, ⁴Health Research Institute of Santiago de Compostela, ⁵Family and Community Medicine, Pontevedra, ⁶Nursing Staff, University Hospital Complex of Santiago de Compostela, ⁷Department of Radiology, University Hospital Complex of Santiago de Compostela, Spain

ABSTRACT

Objectives: The study aimed to identify the factors related to prolonged stay in those patients admitted with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to our hospital. Methods: We conducted a retrospective study by reviewing the medical records of all patients admitted with AECOPD to the University Hospital Complex of Santiago de Compostela in 2007 and 2008. To identify variables independently associated with length of stay, we conducted a logistic regression including those variables which proved to be significant in the univariate analysis. Results: Six hundred and sixty-one patients were assessed; 76.6% were male and the mean age was 74.5 years (standard deviation [SD]: 11.48). The mean stay was 11.9 days (SD: 8) and 24% of all patients required prolonged stay. Factors associated with prolonged mean stay in multivariate analysis were admission to the Intensive Care Unit (odds ratio [OR], 14.7), hospitalization by internal medicine (OR, 2.1), and use of noninvasive mechanical ventilation (OR, 1.75). Conclusions: Prolonged stay in AECOPD is primarily related to the unit patients are admitted to, and to the need for more intensive care.

KEY WORDS: Chronic obstructive pulmonary disease exacerbation, hospital admission, predictors, prolonged stay

INTRODUCTION

With high prevalence, chronic obstructive pulmonary disease (COPD) is a major health care issue globally.¹ Acute exacerbations of COPD (AECOPD) are frequent in the course of the disease, they are associated with high morbidity and mortality,¹,² and they account – especially those acute exacerbation episodes requiring hospitalization – for a large share of treatment costs.¹ Admission costs partly depend on the length of stay.¹⁰ Previous studies have shown great variability in COPD management across hospitals¹⁴ and countries.¹³ Such variability partly depends on the characteristics of both patients and admitting hospitals. Identifying the factors influencing mean stay could improve resource use and efficiency.

The aim of this study is to identify the factors related to prolonged stay in those patients admitted with AECOPD to our hospital.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:  
Website:  
www.lungindia.com

DOI:  
10.4103/lungindia.lungindia_469_17

How to cite this article: García-Sanz MT, González-Barcala FJ, Cánive-Gómez JC, García-Couceiro N, Alonso-Acuña S, Carreira JM. Prolonged stay predictors in patients admitted with chronic obstructive pulmonary disease acute exacerbation. Lung India 2018;35:316-20.
METHODS

Ethical approval
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As it is a retrospective study, formal consent is not required.

We conducted a retrospective study by reviewing the medical records of all patients admitted with AECOPD to the University Hospital Complex of Santiago de Compostela in 2007 and 2008. Data were retrieved from the hospital database and included all patients admitted to the internal medicine unit (IMU) and pneumology unit. For each patient, we reviewed the first admission with AECOPD in the study period, and we excluded all those patients with different reasons for admission, such as pneumonia or acute pulmonary edema, as well as those deceased during admission. The study sample includes 661 patients, whose baseline characteristics, comorbidities, AECOPD characteristics, and analyses conducted both at the emergency department (ED) and during the stay were recorded.

COPD diagnosis and baseline severity were defined following GOLD criteria. In those cases with no spirometry available, COPD diagnosis was accepted by consensus of the research team for patients with a smoking history and clinical and radiological characteristics consistent with such diagnostic hypothesis. Patients who had quitted smoking at least a year before the moment of admission were considered former smokers.

Alcohol users were sorted into four different categories: those consuming over 1 g alcohol/day (regular drinkers), those consuming <1 g alcohol/day (occasional drinkers), those who quitted at least a year before (former drinkers), and never drinkers. Comorbidity was assessed with the Charlson index and categorized into three groups: patients scoring “0,” “1 or 2,” and “over 2” points, respectively. COPD baseline therapy was noted: short-acting and long-acting beta2-agonist inhalers, oral or inhaled corticosteroids, anticholinergics, theophylline, oxygen therapy, and noninvasive mechanical ventilation (NIV) at home. The use of at least 5 mg prednisone/day for at least 3 months in a row was considered chronic steroid therapy.

Weekends were defined as the period between Friday midnight and Sunday midnight.

Patients with prolonged stay were identified as those staying over the 75th percentile of length of stay in our sample, in our case 14 days.

Vital signs and arterial blood gas values were obtained upon patient arrival to the ED. In those cases where no blood gas was determined, a record of O2 saturation by pulse oximetry was obtained. Data from the CBC and serum biochemistry tests conducted on the first sample obtained upon arrival to the hospital were recorded.

Statistical analysis
Data obtained were expressed as mean values ± standard deviation (SD) for continuous variables and as frequencies and percentages for categorical variables. Continuous variables were compared with either Student’s t-test or with Wilcoxon’s test; as for categorical variables, they were compared with the Chi-squared and Fisher’s exact tests. To identify variables independently associated with length of stay, we conducted a logistic regression including those variables with P ≤ 0.05 in the univariate analysis. We considered statistically significant those variables associated with P < 0.05. Data were analyzed with SPSS 15.

RESULTS
A number of 661 patients were assessed; 76.6% were male and the mean age was 74.5 years (SD: 11.48). The mean stay was 11.9 days (SD: 8), and 24% of all patients required prolonged stay (14 days). Patients’ baseline characteristics are shown in Table 1. Acute exacerbation characteristics and complementary test results are shown in Table 2. The following factors were significantly associated with prolonged stay: older age (P = 0.02), chronic kidney disease (P = 0.008), hospitalization by the IMU (P < 0.0001), lower hemoglobin count (P = 0.001), need for admission to the Intensive Care Unit (ICU) (P < 0.0001), and the need for NIV (P = 0.04).

Factors associated with prolonged mean stay in multivariate analysis were admission to the ICU, hospitalization by the IMU, and the need for NIV [Table 3].

DISCUSSION
Prolonged stay may identify more fragile patients who may need more careful attention. The parameters better identifying prolonged stay in our study are primarily related to the unit patients are admitted to, and to the need for more intensive care.

By patients with AECOPD, severe dyspnea unresponsive to treatment, altered state of consciousness, PO2 worsening, acidosis, the need for mechanical ventilation, and hemodynamic instability are considered indicators of admission to the ICU. This is, admission to the ICU seems related to AECOPD severity, to the occurrence of AECOPD-related complications, or to the decompensation of preexisting comorbidities. 2.6% of all our patients required admission to the ICU. As baseline characteristics in these patients did not differ from those admitted to the conventional hospitalization ward, it seems reasonable to attribute ICU admission to AECOPD severity or to the
occurrence of complications. Previous studies related prolonged stay to mechanical ventilation and to the occurrence of complications during stay.\textsuperscript{[18,19]} With ICU admission figures similar to ours, Quintana et al. found an association between length of stay due to AECOPD and the stay in the ICU in their study.\textsuperscript{[20]} This is, AECOPD severity – and not COPD baseline severity – seems to affect the mean length of stay.

In our study, patients with AECOPD admitted to the IMU stayed longer compared to those admitted to the pneumology unit. Several factors could at least partially explain these differences: on the one hand, patients admitted to the ICU were older and scored more frequently higher in the Charlson Index, and older age and number of comorbidities had both been associated with longer stays in previous studies.\textsuperscript{[20]} The percentage of patients with atrial fibrillation and ischemic heart disease was higher among those admitted to the IMU; both conditions are subject to decompensation with beta2-agonist and anticholinergics used to treat AECOPD, and subsequent complications could affect the length of stay.\textsuperscript{[21–23]} However, the contribution by these factors does not seem relevant in our patients, since none of them was independently related to longer stays in previous studies.\textsuperscript{[20]}

Table 1: Patient baseline characteristics

| Hospital stay | \( \leq 14 \text{ days (n=502)} \) | \( >14 \text{ days (n=159)} \) | \( P \) |
|---------------|----------------------------------|-------------------------------|------|
| Age (mean±SD) | 73.9 (11.7)                      | 76.3 (10.4)                   | 0.02 |
| Gender (males) | 384 (76.5)                       | 122 (76.7)                    | 0.9  |
| Tobacco use   |                                  |                               |      |
| Never smokers | 119 (74.8)                       | 40 (25.2)                     | 0.3  |
| Active smokers| 94 (76.4)                        | 29 (23.6)                     |      |
| Former smokers| 162 (72.6)                       | 61 (27.4)                     |      |
| OH use        |                                  |                               |      |
| Regular drinkers | 142 (76.8)                  | 37 (23.2)                     | 0.1  |
| Occasional drinkers | 16 (76.2)                   | 5 (23.8)                      |      |
| Never drinkers | 40 (66.7)                       | 20 (33.3)                     |      |
| Former drinkers | 151 (80.7)                    | 36 (19.3)                     |      |
| GOLD          |                                  |                               |      |
| I             | 59 (17.7)                        | 12 (11.5)                     | 0.1  |
| II            | 137 (41.1)                       | 42 (40.4)                     |      |
| III           | 7 (2.1)                          | 2 (1.9)                       |      |
| IV            | 130 (39)                         | 48 (46.2)                     |      |
| Comorbidities |                                  |                               |      |
| AF/atrial flutter | 125 (25.1)                  | 41 (25.9)                     | 0.8  |
| Hypertension  | 249 (49.6)                       | 79 (49.7)                     | 0.9  |
| Diabetes      | 122 (24.4)                       | 37 (23.4)                     | 0.8  |
| Ischemic heart disease | 100 (20)                 | 28 (17.6)                     | 0.5  |
| Cancer        | 62 (12.4)                        | 23 (14.5)                     | 0.4  |
| Cerebrovascular accident | 48 (9.6)              | 22 (13.8)                     | 0.1  |
| Dementia      | 23 (4.6)                         | 5 (3.1)                       | 0.4  |
| Chronic kidney disease | 35 (7)                  | 22 (13.8)                     | 0.008 |
| Liver disease | 35 (7)                           | 8 (5)                         | 0.3  |
| Charlson Index |                                  |                               |      |
| 0             | 3 (100)                          | 0 (0)                         | 0.2  |
| 1             | 188 (78.7)                       | 51 (21.3)                     |      |
| 2 or more     | 308 (74.2)                       | 107 (25.8)                    |      |
| Baseline therapy |                                  |                               |      |
| Inhaled anticholinergics | 274 (60)                 | 93 (66.4)                     | 0.1  |
| SABA          | 165 (36.1)                       | 48 (34.5)                     | 0.7  |
| LABA          | 269 (58.9)                       | 73 (52.5)                     | 0.1  |
| Inhaled corticosteroids | 274 (60)                  | 81 (58.3)                     | 0.7  |
| Theophylline  | 22 (4.8)                         | 7 (5)                         | 0.9  |
| Oral corticosteroids | 23 (5)                   | 10 (7.2)                      | 0.3  |
| Oxygen therapy at home | 126 (25.1)              | 47 (29.6)                     | 0.2  |
| NIV at home   | 34 (6.8)                         | 15 (10.1)                     | 0.1  |
| Admissions due to AECOPD-previous year | 137 (27.6) | 47 (29.9) | 0.5 |
| AECOPD-previous year Emergency due to AECOPD-previous year | 199 (40.2) | 55 (35.3) | 0.2 |

AF: Atrial fibrillation, SABA: Short-acting beta2 agonists, LABA: Long-acting beta2 agonists, NIV: Noninvasive ventilation, AECOPD: Acute exacerbation of chronic obstructive pulmonary disease, SD: Standard deviation, GOLD: Global initiative for chronic obstructive lung disease.

Table 2: Characteristics of acute exacerbation (univariate analysis)

| Hospital stay | \( \leq 14 \text{ days (n=502)} \) | \( >14 \text{ days (n=159)} \) | \( P \) |
|---------------|----------------------------------|-------------------------------|------|
| HR            | 89.9 (19.4)                      | 89.6 (19.3)                   | 0.8  |
| SBP           | 131 (23.2)                       | 131 (27.2)                    | 0.8  |
| DBP           | 74 (13.6)                        | 73 (13.2)                     | 0.3  |
| BT ≥38°C      | 152 (30.3)                       | 48 (30.2)                     | 0.9  |
| Tachypnea     | 190 (55.4)                       | 61 (63.5)                     | 0.1  |
| Weekend admission | 110 (21.9)                | 32 (20.1)                     | 0.6  |
| Admission unit |                                  |                               |      |
| Pneumology    | 379 (80.8)                       | 90 (19.2)                     | <0.0001 |
| IMU           | 123 (64.1)                       | 69 (35.9)                     |      |
| Laboratory data, n (SD) |                                  |                               |      |
| Hemoglobin    | 13.7 (2.05)                      | 13 (2.4)                      | 0.001 |
| Platelets     | 247,321 (99193)                  | 255,589 (112,969)             | 0.3  |
| Leukocytes    | 11,600 (5640)                    | 11,500 (4665)                 | 0.8  |
| Glucose admission | 144 (70)                  | 142 (59)                      | 0.7  |
| Creatinine admission | 1.1 (0.6)               | 1.1 (0.5)                     | 0.7  |
| Total protein count | 6.3 (6.0)                  | 6.4 (7.0)                     | 0.6  |
| Albumin       | 3.9 (3.6)                        | 3.6 (4.0)                     | 0.3  |
| Fibrinogen    | 456 (150)                        | 427 (143)                     | 0.1  |
| Initial blood gas, n (SD) |                                  |                               |      |
| pH            | 7.4 (0.08)                       | 7.4 (0.07)                    | 0.4  |
| PO\(_2\)      | 47.4 (15.5)                      | 47.4 (17.5)                   | 0.9  |
| PO\(_4\)      | 58.4 (20.4)                      | 57.5 (16.6)                   | 0.5  |
| Bicarbonate   | 28.4 (5.3)                       | 29 (6.6)                      | 0.2  |
| SatO\(_2\)    | 89 (43)                          | 87 (6.7)                      | 0.6  |
| O\(_2\)/FiO\(_2\) | 241 (64)                   | 242 (55)                      | 0.8  |
| Chest radiograph |                                  |                               |      |
| Pleural effusion | 71 (14.2)                  | 17 (10.7)                     | 0.2  |
| Cardiomegaly  | 150 (29.9)                       | 38 (23.9)                     | 0.1  |
| Atelectasis   | 25 (5)                           | 8 (5)                         | 0.9  |
| Bronchectasis | 20 (4)                           | 8 (5)                         | 0.5  |
| ICU           | 3 (0.6)                          | 14 (8.8)                      | <0.0001 |
| NIV           | 66 (13.1)                        | 31 (19.5)                     | 0.04 |
| Antibiotic therapy | 435 (86.7)                | 143 (89.9)                    | 0.2  |

HR: Heart rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, BT: Body temperature, IMU: INTERNAL Medicine Unit, ICU: Intensive Care Unit, NIV: Noninvasive ventilation, SD: Standard deviation.
respiratory effort. Early NIV use is recommended in patients admitted with moderate and severe AECOPD. In our sample, 14.7% of all patients were treated with NIV, and this was associated with longer stays, as in the study by Zacho Priess Leere and Moller Weinreich. According to other authors, patients treated with NIV stay shorter than those treated with mechanical ventilation; however, patients treated with NIV stay longer and with worse outcomes in the event of NIV failure.

Our results should be interpreted with caution due to the limitations inherent to retrospective studies, including selection bias and the assumption that the information in the files reflects clinical practice. Furthermore, as our data come from a single hospital, they might not be generalized to other populations.

CONCLUSIONS

Prolonged stay likelihood by AECOPD hospitalizations is higher in those patients assisted by the IMU, in those admitted to the ICU, and in those requiring NIV.

Acknowledgment

We would like to acknowledge S. García Sanz for the translation of the manuscript.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated; 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf. [Last accessed on 2016 Feb 11].
2. Lima FV, Yen TY, Patel JK. Trends in in-hospital outcomes among adults hospitalized with exacerbation of chronic obstructive pulmonary disease. COPD 2015;12:636-42.
3. Sullivan SD, Ramsey SD, Lee TA. Trends in in-hospital outcomes among adults hospitalized with exacerbation of chronic obstructive pulmonary disease. COPD 2015;12:636-42.
4. Rivás-Ruíz F, Redondo M, González N, Vidal S, García S, Lafuente I, et al. Appropriateness of diagnostick effort in hospital emergency room attention for episodes of COPD exacerbation. J Eval Clin Pract 2015;21:848-54.
5. López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM; European COPD Audit Team. Variability of hospital resources for acute care of COPD patients: The European COPD audit. Eur Respir J 2014;43:754-62.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report 2006. Updated: November, 2006. Available from: http://www.goldcopd.org/workshop/index.html. [Last accessed on 2013 Oct 01].
7. Kadhim-Saleh A, Green M, Williamson T, Hunter D, Bithwhistle R. Validation of the diagnostic algorithms for 5 chronic conditions in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN): A Kingston Practice-Based Research Network (PBRN) report. J Am Board Fam Med 2013;26:159-67.
8. Pace E, Ferraro M, Minervini M, Vitulo P, Pipitone L, Chiappara G, et al. Beta defensin-2 is reduced in central but not in distal airways of smoker COPD patients. PLoS One 2012;7:e33601.
9. Im HJ, Park SM, Choi JH, Choi EJ. Binge drinking and its relation to metabolic syndrome in Korean adult men. Korean J Fam Med 2014;35:173-81.
10. Costa GR, Berjón MF, Mochales JA, Maleras RG, Loso AR, Vasallo MD, et al. Epidemiological features of comorbidity and its influence on the use of health services from Health Survey Madrid 2007, Spain. Rev Esp Salud Publica 2009;83:835-46.
11. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
12. Dewarn NA, Rafique S, Kanwar B, Salpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest 2000;117:662-71.
13. Barba R, Zapatero A, Losa JE, Marco J, Plaza S, Rosado C, et al. The impact of weekends on outcomes for acute exacerbations of COPD. Eur Respir J 2012;39:46-50.
14. Quintana JM, Unzurrunzaga A, García-Gutierrez S, González N, Lafuente I, Bare M, et al. Predictors of hospital length of stay in patients with exacerbations of COPD: A Cohort Study. J Gen Intern Med 2015;30:824-31.
15. Roche N, Rabbat A, Zureik M, Huchon G. Chronic obstructive pulmonary disease exacerbations in emergency departments: Predictors of outcome. Curr Opin Pulm Med 2010;16:112-7.
16. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chron Obstruct Pulmon Dis 2014;9:99-105.
17. Bahoulou M, Chaari A, Tounsi A, Baccouche N, Abid H, Chtria K, et al. Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases. Clin Respir J 2015;9:270-7.
18. Limswat C, Mankongpaisarnrong C, Dumrongmongcolgul N, Nugent K. Factors influencing the length of hospital stay in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to Intensive Care Units. Qual Manag Health Care 2014;23:86-93.
19. Makhoul N, Khamissy-Farah R, Farah R. Length of stay and outcome of hospitalized chronic obstructive pulmonary disease patients, differences between general medical ward and Intensive Care Unit: A Cohort Study. West Indian Med J 2013;62:738-43.
20. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in blackpool admitted with COPD: A cross-sectional study. BMJ Open 2012;2: pii: e000869.
21. Lee CH, Choi S, Jung EJ, Yang HM, Yoon HI, Kim YJ, et al. Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol 2015;190:133-9.
22. van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 1997;84:148-54.
23. Mathew J, Hunsberger S, Fleg J, Mc Sherry F, Williford W, Yusuf S, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-22.
24. Pothirat C, Liwsrisakun C, Bumroongkit C, Deesomchok A, & et al. The economic burden of COPD. Chest 2015;12:636-42.
25. Wijayaratne K, Wilson J, Sivakumaran P, Sriam KB. Differences in care between general medicine and respiratory specialists in the management of patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Thorac Med 2013;8:197-203.

26. Zacho Priess Leere M, Møller Weinreich U. Mortality and readmissions in patients with acute exacerbation of chronic obstructive pulmonary disease treated at a specialised pulmonary ward and general wards. Dan Med J 2014;61:A4938.

27. Stefan MS, Nathanson BH, Higgins TL, Steingrub JS, Lagu T, Rothberg MB, et al. Comparative effectiveness of noninvasive and invasive ventilation in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2015;43:1386-94.